Stereotaxis to Present Niobe(R) System Technology at Japan Heart Rhythm Society
July 21 2014 - 6:30AM
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will
present at the 29th Annual Meeting of the Japanese Heart Rhythm
Society in Tokyo beginning July 23, 2014. The three-day event is
the first large-scale opportunity for the Company's in-country
distributors, Medix Japan, Inc. and Hokushin Medical Co. Ltd., to
promote the clinical value of the Stereotaxis Niobe® Magnetic
Navigation System for cardiac ablations to the Japan
electrophysiology (EP) market. Stereotaxis entered into an
agreement with the two medical device distributors in February 2014
to market, sell and distribute the Niobe system and disposable
devices to Japanese customers.
Medix Japan and Hokushin Medical have been in active dialogue
with EP physicians on behalf of Stereotaxis. In conjunction with
the commercialization efforts, the companies have been meeting with
prestigious medical centers on the potential for research
collaboration and preparing the necessary filings for regulatory
approval of Stereotaxis' Vdrive™ Robotic Navigation System and
Odyssey™ Information Management Solution product lines.
"We are very pleased with the level of commitment this team has
demonstrated in bringing awareness of our technology to a high
priority market, and we look forward to engaging with the Japanese
EP community at Japan HRS this week," says William C. Mills,
Stereotaxis Chief Executive Officer.
In addition to exhibiting at the event, the Company will be
featured during a one-hour panel discussion on July 25, "Current
Status and Future of Robotic Catheter Mapping and Ablation,"
presented by Dr. Hiroshi Nakagawa (University of Oklahoma Health
Sciences Center) and moderated by Dr. Kenzo Hirao (Tokyo Medical
and Dental University).
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in
the development of robotic cardiology instrument navigation systems
designed to enhance the treatment of arrhythmias and coronary
disease, as well as information management solutions for the
interventional lab. Over 100 issued patents support the Stereotaxis
platform, which helps physicians around the world provide
unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis' core Epoch™ Solution
includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient
information management systems and the Vdrive™ Robotic Navigation
system and consumables.
The core components of Stereotaxis systems have received
regulatory clearance in the U.S., European Union, Canada, China,
Japan and elsewhere. The V-Sono™ ICE catheter manipulator has
received U.S. clearance, and the V-Loop™ variable loop catheter
manipulator and V-CAS™ catheter advancement system have been
submitted for review by the U.S. Food and Drug Administration. For
more information, please visit www.stereotaxis.com
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its ability to continue to manage
expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance
indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, the outcome
of various shareholder litigation filed against Stereotaxis,
competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government
reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the
Company's periodic and other filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release. There can be
no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or
at all because some of these purchase orders and other commitments
are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised,
modified, delayed or canceled, either by their express terms, as a
result of negotiations, or by overall project changes or
delays.
CONTACT: Company Contact:
Marty Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com